Erste Group Bank Has Strong Estimate for MRK FY2026 Earnings

Merck & Co., Inc. (NYSE:MRK) – Research analysts at Erste Group Bank raised their FY2026 earnings per share estimates for shares of Merck & Co., Inc. in a research note issued to investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $2.75 for the year, up from their previous estimate of $2.70. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $2.76 per share.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS.

A number of other equities analysts have also commented on the stock. Barclays raised their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Fourteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.11.

Merck & Co., Inc. Stock Down 0.4%

MRK opened at $130.35 on Wednesday. The stock has a fifty day moving average of $124.58 and a 200-day moving average of $119.47. The company has a market capitalization of $321.59 billion, a P/E ratio of 104.28, a P/E/G ratio of 5.66 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 272.00%.

Insider Activity

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 92,603 shares of company stock worth $11,966,744. Insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Several large investors have recently modified their holdings of MRK. Norges Bank acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $3,997,933,000. Wellington Management Group LLP lifted its stake in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Cardano Risk Management B.V. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $1,012,530,000. Jennison Associates LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $585,192,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Merck & Co., Inc. by 37.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA and European Medicines Agency accepted supplemental applications to expand ENFLONSIA, Merck’s RSV preventive therapy, to additional high-risk young children. The potential broader indication could expand Merck’s infectious-disease portfolio and help diversify revenue beyond oncology. Merck Wins FDA and EMA Review for Broader RSV Use in Children
• Positive Sentiment: Argus raised its price target on MRK from $130 to $145 and reiterated a “buy” rating, adding to a generally favorable analyst view. Recent targets from other firms have also reached the $146–$150 range, reflecting confidence in Keytruda, animal health and the development pipeline.
• Positive Sentiment: Merck’s latest quarterly results exceeded expectations, with revenue of $16.61 billion versus a $16.37 billion consensus estimate and revenue growth of 5.1% year over year. Oncology and animal health were key contributors, while the company maintained 2026 adjusted EPS guidance of $2.66–$2.76. Merck Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Merck declared a quarterly dividend of $0.85, equivalent to $3.40 annually and a yield of roughly 2.6%. The dividend supports the stock’s income appeal, although the reported payout ratio is elevated because current earnings are depressed by unusual factors.
• Neutral Sentiment: Reports discussing a proposal to separate the measles, mumps and rubella vaccine into three shots could create uncertainty around Merck’s vaccine business, including MMR II. Experts say the plan lacks scientific support and is unlikely to proceed. Trump Wants to Split the MMR Vaccine
• Negative Sentiment: Analysts continue to flag falling estimates and the risk from upcoming Keytruda patent expirations, which could pressure Merck’s near-term growth and valuation despite strong current sales and pipeline progress. MRK Stock Up 5.6% in a Month as Estimates Fall
• Negative Sentiment: Executive Vice President Richard Deluca sold 6,050 shares worth approximately $788,799. The sale reduced his holdings by 3.75%, though he continues to own a substantial position and the transaction alone is not necessarily a signal of deteriorating fundamentals. Merck EVP Sells Stock

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.